BioSpace News Archive

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the second quarter ended June 30, 2023.

Verrica Pharmaceuticals Inc. today announced the acceptance of an abstract that will feature clinical data from the Company’s ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma (“BCC”).

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported operational highlights and financial results for the second quarter ended June 30, 2023.

Harpoon Therapeutics, Inc. today announced that management will participate in two upcoming investor conferences.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2023, and provided recent business updates.

Elevation Oncology, Inc. today announced financial results for the second quarter ended June 30, 2023, and highlighted recent business achievements.

Immunic, Inc. announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2023 and provided a business update.

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced that it has signed an agreement to acquire a majority ownership position in Shield Healthcare, Inc., a leading supplier of homecare medical products delivered directly to patients in their homes.

InfuSystem Holdings, Inc., a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, reported financial results for the second quarter ended June 30, 2023.